These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7378171)

  • 41. [Synergic action of the combination of fosfomycin and kanendomycin against gram-positive and gram-negative bacteria].
    Russo G; Toscano MA; Gismondo MR; Nicolosi V; Garaci E
    Ann Sclavo; 1980; 22(1):77-82. PubMed ID: 7247487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasmid-mediated fosfomycin resistance is due to enzymatic modification of the antibiotic.
    Llaneza J; Villar CJ; Salas JA; Suarez JE; Mendoza MC; Hardisson C
    Antimicrob Agents Chemother; 1985 Jul; 28(1):163-4. PubMed ID: 3899003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Fosfomycin resistance in Staphylococcus saprophyticus and other species of coagulase-negative staphylococci].
    Loulergue J; Pinon G; Laudat P; Audurier A
    Ann Microbiol (Paris); 1984; 135A(2):239-47. PubMed ID: 6721325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pathogenecity of fosfomycin-resistant strains isolated from Escherichia coli].
    Kasai T; Tsuruoka T
    Jpn J Antibiot; 1999 Jan; 52(1):34-40. PubMed ID: 10202686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.
    Takahata S; Ida T; Hiraishi T; Sakakibara S; Maebashi K; Terada S; Muratani T; Matsumoto T; Nakahama C; Tomono K
    Int J Antimicrob Agents; 2010 Apr; 35(4):333-7. PubMed ID: 20071153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].
    Gómez-Garcés JL; Gil-Romero Y; Sanz-Rodríguez N; Muñoz-Paraíso C; Regodón-Domínguez M
    Enferm Infecc Microbiol Clin; 2016 Apr; 34(4):228-31. PubMed ID: 26277206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro investigations on the action fosfomycin alone and in combination with other antibiotics on Pseudomonas aeruginosa and Serratia marcescens.
    Ullmann U; Lindemann B
    Arzneimittelforschung; 1980; 30(8):1247-9. PubMed ID: 6776966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Probing transport of fosfomycin through substrate specific OprO and OprP from Pseudomonas aeruginosa.
    Citak F; Ghai I; Rosenkötter F; Benier L; Winterhalter M; Wagner R
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1454-1460. PubMed ID: 29198700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fosfomycin causes transient lysis in Escherichia coli strains carrying fosfomycin-resistance plasmids.
    León J; García-Lobo JM; Navas J; Ortíz JM
    J Gen Microbiol; 1985 Dec; 131(12):3255-60. PubMed ID: 3913742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Mechanism of fosfomycin-resistance in clinical isolates].
    O'Hara K; Hashimoto H
    Jpn J Antibiot; 1996 Jun; 49(6):533-43. PubMed ID: 8776629
    [No Abstract]   [Full Text] [Related]  

  • 53. [Action of phosphomycin in vitro (author's transl)].
    Langsádl L; Schindler J; Budĕsínský Z
    Cesk Epidemiol Mikrobiol Imunol; 1978 Sep; 27(5):289-95. PubMed ID: 152162
    [No Abstract]   [Full Text] [Related]  

  • 54. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa.
    Hamou-Segarra M; Zamorano L; Vadlamani G; Chu M; Sanchez-Diener I; Juan C; Blazquez J; Hattie M; Stubbs KA; Mark BL; Oliver A
    J Antimicrob Chemother; 2017 Feb; 72(2):448-454. PubMed ID: 27999022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of fosfomycin when tested against US contemporary bacterial isolates.
    Flamm RK; Rhomberg PR; Watters AA; Sweeney K; Ellis-Grosse EJ; Shortridge D
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):143-146. PubMed ID: 30236530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection.
    Pourbaix A; Guérin F; Lastours V; Chau F; Auzou M; Boulley E; Cattoir V; Fantin B
    Int J Med Microbiol; 2017 Dec; 307(8):452-459. PubMed ID: 28986014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 59. High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium.
    Guo Y; Tomich AD; McElheny CL; Cooper VS; Tait-Kamradt A; Wang M; Hu F; Rice LB; Sluis-Cremer N; Doi Y
    Emerg Infect Dis; 2017 Nov; 23(11):1902-1904. PubMed ID: 29048285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF.
    Sharma A; Sharma R; Bhattacharyya T; Bhando T; Pathania R
    J Antimicrob Chemother; 2017 Jan; 72(1):68-74. PubMed ID: 27650185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.